Total Payments
$762,875
2024 Payments
$70,255
Companies
36
Transactions
1,089
Medicare Patients
1,428
Medicare Billing
$396,817
Payment Breakdown by Category
Other$501,859 (65.8%)
Consulting$145,055 (19.0%)
Travel$80,838 (10.6%)
Food & Beverage$30,077 (3.9%)
Research$4,875 (0.6%)
Education$171.43 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $251,277 | 117 | 32.9% |
| Honoraria | $171,216 | 104 | 22.4% |
| Consulting Fee | $145,055 | 53 | 19.0% |
| Travel and Lodging | $80,838 | 289 | 10.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $74,300 | 26 | 9.7% |
| Food and Beverage | $30,077 | 487 | 3.9% |
| Unspecified | $4,875 | 8 | 0.6% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $4,385 | 2 | 0.6% |
| Grant | $680.25 | 1 | 0.1% |
| Education | $171.43 | 2 | 0.0% |
Payments by Type
General
$758,000
1,081 transactions
Research
$4,875
2 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $203,926 | 279 | $0 (2024) |
| Edwards Lifesciences Corporation | $118,688 | 174 | $0 (2024) |
| bioMerieux Inc | $99,964 | 89 | $0 (2023) |
| La Jolla Pharmaceutical Company | $90,863 | 95 | $0 (2024) |
| Astute Medical, Inc. | $59,509 | 84 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53,461 | 88 | $0 (2022) |
| Valeant Pharmaceuticals North America LLC | $33,280 | 61 | $0 (2017) |
| AcelRx Pharmaceuticals, Inc. | $31,122 | 41 | $0 (2021) |
| Eagle Pharmaceuticals, Inc. | $30,072 | 19 | $0 (2018) |
| Baudax Bio Inc. | $14,093 | 17 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,255 | 69 | La Jolla Pharmaceutical Company ($45,265) |
| 2023 | $72,410 | 93 | Alexion Pharmaceuticals, Inc. ($42,781) |
| 2022 | $95,836 | 146 | Alexion Pharmaceuticals, Inc. ($72,657) |
| 2021 | $105,530 | 127 | Alexion Pharmaceuticals, Inc. ($51,713) |
| 2020 | $72,378 | 108 | AcelRx Pharmaceuticals, Inc. ($19,297) |
| 2019 | $153,342 | 236 | Edwards Lifesciences Corporation ($56,518) |
| 2018 | $120,217 | 202 | Astute Medical, Inc. ($52,819) |
| 2017 | $72,907 | 108 | Valeant Pharmaceuticals North America LLC ($33,280) |
All Payment Transactions
1,089 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Honoraria | Cash or cash equivalent | $3,698.00 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 12/06/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Honoraria | Cash or cash equivalent | $2,219.00 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 12/06/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 12/06/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $40.44 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 12/05/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Honoraria | Cash or cash equivalent | $3,698.00 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 12/05/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $121.90 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 12/05/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $84.29 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 11/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,550.00 | General |
| Category: Rare Disease | ||||||
| 11/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $88.55 | General |
| Category: Rare Disease | ||||||
| 11/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | Cash or cash equivalent | $56.60 | General |
| Category: Rare Disease | ||||||
| 10/29/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Honoraria | Cash or cash equivalent | $2,959.00 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 10/29/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $115.52 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 10/24/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Honoraria | Cash or cash equivalent | $5,177.00 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 10/24/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $84.22 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 10/24/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Travel and Lodging | Cash or cash equivalent | $79.31 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 10/18/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $5.00 | General |
| 10/17/2024 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,060.00 | General |
| 10/17/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $125.96 | General |
| 10/17/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 10/17/2024 | Merck Sharp & Dohme LLC | BRIDION (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: NEUROSCIENCE | ||||||
| 09/27/2024 | Fresenius Kabi USA, LLC | Smoflipid (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Parental Nutrition | ||||||
| 09/04/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Honoraria | Cash or cash equivalent | $4,437.90 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 09/04/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Travel and Lodging | Cash or cash equivalent | $1,104.85 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 09/04/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 08/15/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Honoraria | Cash or cash equivalent | $2,219.00 | General |
| Category: EMERGENT HYPOTENSION | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LAPIS Trial: A Biomarker-Guided Implementation of Kidney-Sparing Care Measures to Prevent AKI in Sepsis Patients | bioMerieux | $4,875 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 373 | 410 | $345,948 | $33,019 |
| 2022 | 7 | 336 | 563 | $468,615 | $76,651 |
| 2021 | 8 | 308 | 739 | $568,386 | $117,121 |
| 2020 | 8 | 411 | 1,056 | $827,020 | $170,026 |
Total Patients
1,428
Total Services
2,768
Medicare Billing
$396,817
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 00731 | Anesthesia for other procedure on esophagus, stomach, or upper small bowel using an endoscope | Facility | 2023 | 138 | 145 | $122,640 | $9,154 | 7.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 28 | 52 | $43,075 | $8,851 | 20.5% |
| 00813 | Anesthesia for procedure on small and large bowel using an endoscope | Facility | 2023 | 82 | 82 | $81,060 | $6,186 | 7.6% |
| 00811 | Anesthesia for other procedure on large bowel using an endoscope | Facility | 2023 | 52 | 52 | $43,890 | $3,168 | 7.2% |
| 00520 | Anesthesia for other closed procedure on chest | Facility | 2023 | 20 | 21 | $22,470 | $1,692 | 7.5% |
| 00142 | Anesthesia for lens surgery | Facility | 2023 | 18 | 18 | $13,078 | $1,556 | 11.9% |
| 00812 | Anesthesia for exam of colon using an endoscope | Facility | 2023 | 22 | 22 | $15,540 | $1,509 | 9.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 18 | $4,195 | $903.98 | 21.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 126 | 350 | $296,100 | $62,058 | 21.0% |
| 00731 | Anesthesia for other procedure on esophagus, stomach, or upper small bowel using an endoscope | Facility | 2022 | 91 | 91 | $77,175 | $6,010 | 7.8% |
| 00813 | Anesthesia for procedure on small and large bowel using an endoscope | Facility | 2022 | 33 | 33 | $34,230 | $2,598 | 7.6% |
| 00811 | Anesthesia for other procedure on large bowel using an endoscope | Facility | 2022 | 31 | 31 | $26,145 | $2,051 | 7.8% |
| 00812 | Anesthesia for exam of colon using an endoscope | Facility | 2022 | 25 | 25 | $18,480 | $1,790 | 9.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 21 | $4,515 | $1,198 | 26.5% |
| 00520 | Anesthesia for other closed procedure on chest | Facility | 2022 | 12 | 12 | $11,970 | $946.13 | 7.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 170 | 567 | $480,822 | $102,588 | 21.3% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2021 | 22 | 45 | $34,875 | $4,594 | 13.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 39 | 47 | $10,199 | $2,744 | 26.9% |
| 31500 | Emergent insertion of breathing tube into windpipe cartilage using an endoscope | Facility | 2021 | 21 | 21 | $9,450 | $2,545 | 26.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 20 | $6,220 | $1,677 | 27.0% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2021 | 11 | 13 | $4,875 | $1,184 | 24.3% |
| 00811 | Anesthesia for procedure on large bowel using an endoscope | Facility | 2021 | 13 | 13 | $11,865 | $958.94 | 8.1% |
| 00731 | Anesthesia for procedure on esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 13 | 13 | $10,080 | $830.36 | 8.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 227 | 766 | $653,856 | $139,734 | 21.4% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2020 | 35 | 117 | $88,648 | $12,092 | 13.6% |
About Dr. Louis Guzzi, MD
Dr. Louis Guzzi, MD is a Critical Care Medicine healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1215923180.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Louis Guzzi, MD has received a total of $762,875 in payments from pharmaceutical and medical device companies, with $70,255 received in 2024. These payments were reported across 1,089 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($251,277).
As a Medicare-enrolled provider, Guzzi has provided services to 1,428 Medicare beneficiaries, totaling 2,768 services with total Medicare billing of $396,817. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Anesthesiology
- Location Orlando, FL
- Active Since 09/26/2005
- Last Updated 04/28/2023
- Taxonomy Code 207LC0200X
- Entity Type Individual
- NPI Number 1215923180
Products in Payments
- GIAPREZA (Drug) $90,733
- Nephrocheck (Device) $52,819
- NEPHROCHECK TEST (Device) $50,008
- RELISTOR (Drug) $43,280
- ULTOMIRIS (Biological) $38,544
- XIFAXAN (Drug) $35,528
- DSUVIA (Drug) $31,122
- Ryanodex Single Use Only - 250ml (Drug) $27,334
- NEPHROCHECK (Device) $20,768
- ANDEXXA (Biological) $17,077
- Ultomiris (Drug) $14,623
- ANJESO (Drug) $14,093
- Andexxa (Drug) $9,908
- BEVYXXA (Drug) $8,046
- LUCEMYRA (Drug) $7,933
- NEPHROCHECK LIQUID CONTROL KIT (Device) $6,789
- NephroCheck Test (Device) $6,690
- NEPROCHECK (Device) $4,875
- Smoflipid (Drug) $4,600
- NephroCheck Test Kit (Device) $3,798
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Orlando
Junaid Malik, Md, MD
Critical Care Medicine — Payments: $474,851
Critical Care Medicine $474,851
Dr. Omid Zad, Md, MD
Critical Care Medicine — Payments: $334,047
Critical Care Medicine $334,047
Debabrata Bandyopadhyay, Md, MD
Critical Care Medicine — Payments: $307,159
Critical Care Medicine $307,159
Charles Hunley, M.d, M.D
Critical Care Medicine — Payments: $254,349
Critical Care Medicine $254,349
Dr. Dmitriy Zubkus, M.d, M.D
Critical Care Medicine — Payments: $62,293
Critical Care Medicine $62,293
Hammad Bhatti, M.d.,, M.D.,
Critical Care Medicine — Payments: $51,853
Critical Care Medicine $51,853